The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease

Figures & data

Table 1 Comparison of the data of the CHB patients with and without nonalcoholic fatty liver disease

	Group A (n=61)	Group B (n=64)	t	P-value
Age (years), mean ± SD	39.26±10.39	39.61±10.87	0.18	>0.05
Sex
Male (n)	42	41	0.32	>0.05
Female (n)	19	23
BMI (kg/m^2), mean ± SD	26.29±3.99	22.50±2.85	6.11	<0.05
WC (cm), mean ± SD	89.88±11.25	79.84±9.99	5.28	<0.05
ALT (U/L), mean ± SD	179.87±78.50	187.95±79.88	0.57	>0.05
HBV-DNA (lg copies/mL), mean ± SD	6.24±0.78	6.20±0.64	0.31	>0.05
Genotyping
HBV genotype B (%)	38	42	0.15	>0.05
HBV genotype C (%)	23	22
HOMA-IR, mean ± SD	3.67±3.89	2.07±1.98	3.6	<0.05
FINS (mU/L), mean ± SD	15.46±10.93	9.03±7.36	3.84	<0.05
FBG (mmol/L), mean ± SD	5.11±0.85	4.89±0.80	1.52	>0.05
TG (mmol/L), mean ± SD	1.80±0.95	1.33±0.64	3.29	<0.05
TC (mmol/L), mean ± SD	3.78±1.07	3.72±0.97	0.31	>0.05
HDL-C (mmol/L), mean ± SD	0.86±0.34	1.07±0.35	3.32	<0.05
LDL-C (mmol/L), mean ± SD	2.31±0.72	2.16±0.68	1.15	>0.05

Notes: Group A: NAFLD patients with HBeAg-positive CHB; Group B: patients with simple CHB.

Abbreviations: CHB, chronic hepatitis B; BMI, body mass index; WC, waist circumference; ALT, alanine transaminase; HBV, hepatitis B virus; HOMA-IR, homeostatic model assessment method insulin resistance; FINS, fasting serum insulin; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease.

Table 2 Comparison of the HBV-DNA untestable rate between the study groups at different follow-up time points

	Group A (n=61)	Group B (n=64)	χ^2	P-value
12 weeks	20 (32.8%)	33 (51.6%)	4.508	0.034
24 weeks	32 (52.5%)	41 (64.1%)	1.731	0.188
48 weeks	38 (62.3%)	48 (75.0%)	2.349	0.125
96 weeks	50 (82.0%)	55 (85.9%)	0.366	0.545

Notes: Group A: NAFLD patients with HBeAg-positive CHB; Group B: patients with simple CHB.

Abbreviations: CHB, chronic hepatitis B; HBV, hepatitis B virus; NAFLD, nonalcoholic fatty liver disease.

Table 3 Comparison of the HBeAg seroconversion rate between the study groups at follow-up time points

	Group A (n=61)	Group B (n=64)	χ^2	P-value
48 weeks	13 (21.3%)	15 (29.5%)	0.081	0.776
96 weeks	18 (23.4%)	21 (32.8%)	0.159	0.69

Notes: Group A: NAFLD patients with HBeAg-positive CHB; Group B: patients with simple CHB.

Abbreviations: CHB, chronic hepatitis B; NAFLD, nonalcoholic fatty liver disease.

Table 4 Comparison of the ALT normalization rate between the study groups at different follow-up time points

	Group A (n=61)	Group B (n=64)	χ^2	P-value
12 weeks	31 (50.8%)	38 (59.4%)	0.924	0.336
24 weeks	34 (55.7%)	42 (65.6%)	1.281	0.258
48 weeks	40 (65.6%)	52 (81.3%)	2.95	0.047
96 weeks	50 (82.0%)	60 (93.8%)	4.106	0.043

Notes: Group A: NAFLD patients with HBeAg-positive CHB; Group B: patients with simple CHB.

Abbreviations: ALT, alanine transaminase; CHB, chronic hepatitis B; NAFLD, nonalcoholic fatty liver disease.

Table 5 Comparison of the ALT normalization rate between group A patients with different baseline levels of HOMA-IR at follow-up time points

Group	Patients (n)	ALT normalization rate, n (%)		χ^2	P-value
		48 weeks	96 weeks
A1	31	24 (77.4%)	29 (93.5%)	3.918	0.048
A2	30	16 (53.3%)	21 (70.0%)	5.72	0.017

Notes: Group A: NAFLD patients with HBeAg-positive CHB; Group A1: HOMA-IR ≤ median (2.79); Group A2: HOMA-IR > median (2.79).

Abbreviations: ALT, alanine transaminase; CHB, chronic hepatitis B; HOMA-IR, homeostatic model assessment method insulin resistance; NAFLD, nonalcoholic fatty liver disease.

Table 6 Correlation analysis between the severity of fatty liver and HOMA-IR

Severity	Patients (n)	HOMA-IR, mean ± SD
Mild	30	2.57±1.39
Moderate	22	3.54±2.11
Serious	9	7.67±4.61

Note: Spearman correlation analysis, r=0.426, P=0.001 (positive correlation).

Abbreviation: HOMA-IR, homeostatic model assessment method insulin resistance.